The suit alleges that Natera's Panorama test infringes US Patent No. 9,493,831 patent, which covers sequencing library preparation methods applied to maternal blood samples.
In Q4 Natera tallied revenues of $53.8 million compared to $49.3 million a year ago, falling short of the consensus Wall Street estimate of $57.1 million.
Natera outlined its work with pharmaceutical firms to use the Signatera assay, while Luminex was bullish about its growing molecular diagnostics business.
Natera said its liquid biopsy assay Signatera is well suited for the immuno-oncology field, particularly pharmaceutical companies developing personalized vaccines.
In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.
